MX2023003771A - Composiciones y metodos para el diagnostico del cancer. - Google Patents
Composiciones y metodos para el diagnostico del cancer.Info
- Publication number
- MX2023003771A MX2023003771A MX2023003771A MX2023003771A MX2023003771A MX 2023003771 A MX2023003771 A MX 2023003771A MX 2023003771 A MX2023003771 A MX 2023003771A MX 2023003771 A MX2023003771 A MX 2023003771A MX 2023003771 A MX2023003771 A MX 2023003771A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- present disclosure
- gangliosides
- compositions
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
- G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063087427P | 2020-10-05 | 2020-10-05 | |
| PCT/US2021/053503 WO2022076364A1 (en) | 2020-10-05 | 2021-10-05 | Compositions and methods for cancer diagnosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003771A true MX2023003771A (es) | 2023-06-22 |
Family
ID=81126198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003771A MX2023003771A (es) | 2020-10-05 | 2021-10-05 | Composiciones y metodos para el diagnostico del cancer. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250277793A1 (https=) |
| EP (1) | EP4225365A4 (https=) |
| JP (1) | JP2023553247A (https=) |
| KR (1) | KR20230155419A (https=) |
| CN (1) | CN117120086A (https=) |
| AU (1) | AU2021357695A1 (https=) |
| CA (1) | CA3197304A1 (https=) |
| IL (1) | IL301783A (https=) |
| MX (1) | MX2023003771A (https=) |
| WO (1) | WO2022076364A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315829A (en) * | 2022-04-04 | 2024-11-01 | Aoa Dx | Mass spectrometry methods for cancer diagnosis |
| WO2025096441A1 (en) * | 2023-10-30 | 2025-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Ganglioside gm2 as a target for cancer immunotherapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2329897A1 (en) * | 1998-04-28 | 1999-11-04 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
| ES2904533T3 (es) * | 2013-12-06 | 2022-04-05 | Aoa Dx | Compuesto antigangliósido para dirigirlo contra el cáncer y generar anticuerpos |
| WO2017048823A1 (en) * | 2015-09-18 | 2017-03-23 | Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation | Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof |
| WO2018112669A1 (en) * | 2016-12-23 | 2018-06-28 | Realist Pharma, Inc. | Ganglioside carbohydrate structures and uses thereof |
-
2021
- 2021-10-05 WO PCT/US2021/053503 patent/WO2022076364A1/en not_active Ceased
- 2021-10-05 IL IL301783A patent/IL301783A/en unknown
- 2021-10-05 MX MX2023003771A patent/MX2023003771A/es unknown
- 2021-10-05 EP EP21878327.2A patent/EP4225365A4/en active Pending
- 2021-10-05 CA CA3197304A patent/CA3197304A1/en active Pending
- 2021-10-05 CN CN202180081628.7A patent/CN117120086A/zh active Pending
- 2021-10-05 KR KR1020237014431A patent/KR20230155419A/ko active Pending
- 2021-10-05 US US18/030,426 patent/US20250277793A1/en active Pending
- 2021-10-05 AU AU2021357695A patent/AU2021357695A1/en active Pending
- 2021-10-05 JP JP2023521107A patent/JP2023553247A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4225365A4 (en) | 2024-11-13 |
| EP4225365A1 (en) | 2023-08-16 |
| AU2021357695A1 (en) | 2023-06-01 |
| CN117120086A (zh) | 2023-11-24 |
| US20250277793A1 (en) | 2025-09-04 |
| KR20230155419A (ko) | 2023-11-10 |
| IL301783A (en) | 2023-05-01 |
| WO2022076364A1 (en) | 2022-04-14 |
| CA3197304A1 (en) | 2022-04-14 |
| JP2023553247A (ja) | 2023-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019005670A2 (pt) | anticorpos anti-muc16 (mucina 16) | |
| MX2019009967A (es) | Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas. | |
| EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
| EA201990781A9 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| BR112013011065A2 (pt) | "anticorpo anti-il-23p19 ou seu fragmento de ligação ao antígeno, composição farmacêutica, uso de um anticorpo ou do fragmento de ligação, método para inibir a ligação da il-23 para o receptor da il-23 em uma célula de mamífero, polinucleotídeo isolado e kit" | |
| JOP20230311A1 (ar) | أجسام مضادة لـ sirp-ألفا | |
| NO20081124L (no) | Anti-CD 3 antistoff-formuleringer | |
| KR20230145514A (ko) | 엽산 수용체 1의 검출을 위한 항체 및 분석 | |
| NZ593964A (en) | Human anti-alpha-synuclein autoantibodies | |
| MX2010005022A (es) | Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas. | |
| JOP20220070A1 (ar) | مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| MX2021011715A (es) | Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención. | |
| MX2023003771A (es) | Composiciones y metodos para el diagnostico del cancer. | |
| MY204235A (en) | Antibodies specific for cd3 and uses thereof | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| Simpson et al. | A caspase-3 ‘death-switch’in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers | |
| WO2019074333A3 (ko) | 티오레독신 1 에피토프 및 이에 특이적으로 결합하는 단일클론항체 | |
| Napoletano et al. | Investigating patterns of immune interaction in ovarian cancer: probing the O-glycoproteome by the macrophage galactose-like C-type lectin (MGL) | |
| WO2019086480A1 (en) | Anti-cd5l antibody and uses thereof | |
| Ise et al. | Loss of CD38 expression in relapsed refractory multiple myeloma | |
| EA202193040A1 (ru) | Конъюгат анти-всма антитела, композиции, содержащие данный конъюгат, и способы его получения и применения | |
| MX2023002850A (es) | Fragmento de anticuerpo contra proteina activadora de fibroblastos (fap). | |
| BRPI0415541B8 (pt) | uso de uma molécula inibidora de angiogênese, composição terapêutica para tratametno de câncer, e uso do anticorpo h33, produzido pelo hibridoma 13h33 | |
| WO2025081117A3 (en) | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates |